Return On Equity ratio Analysis of MedTech Acquisition Corp - Deep Dive
Birds's Eye
Fundamentals
Fundamentals
Technicals
MovingAverage
Candlestick
PivotPointLatest FY ROE
Period Ending - Dec-22
Poor ROE
0
Period Ending - Dec-21
Poor ROE
1.96
Growth
0 %
Trailing Twelve Months ROE
Period Ending - Dec-22
Poor ROE
4.58
Most recent Quarter ROE
Period Ending - Jun-23
Poor ROE
0
ROE Analysis of MedTech Acquisition Corp
| ROE Ratio of MedTech Acquisition Corp with value of 4.58 means is not able to effectively utilize its Shareholders Fund in order to generate a profit in trailing twelve months. |
| ROE Ratio of MedTech Acquisition Corp with value of 0 means is not able to effectively utilize its Shareholders Fund in order to generate a profit in latest Quarter ending on Jun-23. |
| ROE Ratio of MTAC has fallen by 0 % Compared to previous Financial Year. |
Other ROE Related Info of MTAC that may interest you.
MedTech Acquisition Corp Overview
| Code | Price | Previous Price | Price Change | Sector |
|---|---|---|---|---|
| MTAC | 11.34 | 9.5559 | 18.67 % | Shell Companies |
Defination of Return On Equity
The Return on Equity (ROE) is a profitability metric that measures a company's ability to generate profits using its shareholder's fund. ROE is calculated by dividing Net Income by Shareholders' Fund. more ..
ROE Related Ratios
| ReturnOnAsset | NetProfitMargin |
Tsr Profitability Index
| Poor Profitability Stock | |
FY - Historical Return On Equity of MedTech Acquisition Corp
| Period | Dec-22 | Dec-21 | Dec-20 |
|---|---|---|---|
| ROE | 0 | 1.96 | -0.0433 |
| Change | 0 % | 4631.85 % |
FY Chart of Return On Equity of MedTech Acquisition Corp
Note : All Data Generated at the End of Trading Hours (EOD Data)